AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX)

Historical Holders from Q1 2022 to Q3 2025

Type / Class
Equity / Common Stock and Warrants
Symbol
ANTX on Nasdaq
Shares outstanding
27,467,750
Price per share
$1.27
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
8,276,317
Total reported value
$10,511,010
% of total 13F portfolios
0%
Share change
-8,231
Value change
+$7,414
Number of holders
35
Price from insider filings
$1.27
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Coastlands Capital Partners LP 9.3% $3,632,511 2,815,900 Coastlands Capital LP 28 May 2025
Adjuvant Global Health Technology Fund, L.P. 7.9% $3,061,815 2,373,500 Adjuvant Capital GP, L.P. 31 Dec 2024
Easom Eric 6.2% $2,442,140 1,893,132 Eric Easom 31 Dec 2024
Almitas Capital LLC 5.2% $1,813,970 1,428,323 Almitas Capital LLC 30 Sep 2025
Brii Biosciences Ltd 3.1% $1,196,089 927,201 Brii Biosciences Limited 31 Dec 2024
BML Investment Partners, L.P. 1.4% -85% $551,387 -$3,599,088 427,432 -87% BML Investment Partners, L.P. 17 Jun 2025
As of 30 Sep 2025, AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) has 35 institutional shareholders filing 13F forms. They hold 8,276,317 shares. of 27,467,750 outstanding shares (30%) .

Top 25 institutional shareholders own 30% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Almitas Capital LLC 5.2% 1,428,323 0% 0.42% $1,813,970
VANGUARD GROUP INC 3.9% 1,080,070 +4.3% 0% $1,371,689
Pfizer Inc 2.6% 715,295 0% 0.21% $908,425
Peapod Lane Capital LLC 2.1% 589,216 +1.1% 0.67% $748,317
Stonepine Capital Management, LLC 2.1% 563,913 +3.6% 0.58% $716,170
BANK OF NOVA SCOTIA 1.7% 459,194 0% 0% $583,176
LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 1.7% 456,463 -7.9% 0.04% $579,708
BANK OF MONTREAL /CAN/ 1.5% 422,077 0% 0% $536,038
RENAISSANCE TECHNOLOGIES LLC 1.4% 385,597 -3.3% 0% $489,708
BANK OF AMERICA CORP /DE/ 1.4% 385,310 -0.05% 0% $489,343
BlackRock, Inc. 1.2% 320,911 +0.51% 0% $407,557
TWO SIGMA ADVISERS, LP 0.98% 267,900 -0.63% 0% $340,233
GEODE CAPITAL MANAGEMENT, LLC 0.91% 249,351 0% 0% $316,747
TWO SIGMA INVESTMENTS, LP 0.81% 223,337 -6.3% 0% $283,638
MORGAN STANLEY 0.69% 190,770 +7% 0% $242,278
STATE STREET CORP 0.32% 87,002 0% 0% $110,493
Rangeley Capital, LLC 0.24% 65,000 0% 0.08% $82,550
Squarepoint Ops LLC 0.23% 64,267 +539% 0% $81,619
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.22% 59,900 0% 0% $76,073
UBS Group AG 0.21% 56,694 -8.6% 0% $72,001
NORTHERN TRUST CORP 0.16% 43,196 0% 0% $54,859
CAPTRUST FINANCIAL ADVISORS 0.15% 40,000 0% 0% $50,800
CITADEL ADVISORS LLC 0.08% 23,013 +84% 0% $29,227
Private Advisor Group, LLC 0.08% 22,500 0% 0% $28,575
XTX Topco Ltd 0.07% 18,541 -29% 0% $23,547

Institutional Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 8,276,317 $10,511,010 +$7,414 $1.27 35
2025 Q2 8,284,557 $8,781,263 -$8,600,258 $1.06 36
2025 Q1 14,340,830 $19,503,615 -$264,699 $1.36 37
2024 Q4 14,528,930 $20,050,012 +$893,482 $1.38 37
2024 Q3 13,513,224 $14,458,906 -$16,315,888 $1.07 31
2024 Q2 19,415,909 $41,730,123 -$1,462,207 $2.15 45
2024 Q1 18,733,564 $60,875,021 -$18,042,573 $3.25 54
2023 Q4 20,391,503 $417,920,110 +$9,592,150 $20.49 51
2023 Q3 19,931,490 $320,311,244 +$132,978,201 $16.08 37
2023 Q2 11,741,328 $99,891,167 +$18,097,549 $8.50 30
2023 Q1 9,600,229 $94,752,948 -$1,565,644 $9.87 37
2022 Q4 9,762,608 $93,037,767 -$3,679,262 $9.53 35
2022 Q3 9,496,676 $165,051,000 +$1,938,968 $17.38 35
2022 Q2 9,386,370 $72,410,000 +$2,199,519 $7.75 32
2022 Q1 8,952,537 $134,111,000 +$134,111,000 $15.07 18